Comparison of the Hyperkinasemic Effects of Erythropoietin and U-74389G on Creatine Phosphokinase Levels
1*Department of Gynecology, General Hospital of Thessaloniki “St. Dimitrios” Thessaloniki, Hellas
2Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Athens, Attiki, Hellas
3Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas
4Department of Biologic Chemistry, Athens University, Athens, Attiki, Hellas
5Department of Surgery, Ippokrateion General Hospital, Athens University, Athens, Attiki, Hellas
6, 7Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Hellas
8Experimental, Educational and Research Center ELPEN, European University Cyprus, School of Medicine
Citation: C. Τsompos, C. Panoulis, K Τοutouzas, et al., “Comparison of the Hyperkinasemic Effects of
Erythropoietin and U-74389G on Creatine Phosphokinase Levels”. American Research Journal of Biomedical
Engineering. vol 2, no. 1: 1-7.
Abstract
Aim: This study calculated the effects on creatine phosphokinase (CPK) levels, after treatment with either of 2
drugs: the erythropoietin (Epo) and the antioxidant lazaroid (L) drug U-74389G. The calculation was based on
the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug
usage in an induced ischemia reperfusion (IR) animal experiment.
Materials and Methods: The 2 main experimental endpoints at which the serum CPK levels (CPKl) were
evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the
groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo
administration; whereas groups E and F after the L administration.
Results: The first preliminary study of Epo presented a non significant hyperkinase mice ffect by 2.08%+2.77%
(p-value=0.4430). The second preliminary study of U-74389G presented a significant hyperkinasemic effect
by 8.52%+4.35% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same
experimental setting. The outcome of the co-evaluation was that L is 4.09626-fold [4.092989 - 4.099534] more
hyperkinasemic than Epo (p-value=0.0000).
Conclusions: The anti-oxidant capacities of U-74389G ascribe 4.09626-fold more hyperkinasemic effects than
Epo (p-value=0.0000)
